Avibactam Sodium

Avibactam Sodium is a covalent, reversible non‑β‑lactam β‑lactamase inhibitor used in combination with ceftazidime for the treatment of complicated intra‑abdominal and urinary tract infections, as well as hospital‑acquired pneumonia. As the first in its class, Avibactam Sodium addresses the growing threat of antimicrobial resistance by inhibiting a broad spectrum of β‑lactamases. Avibactam Sodium is supplied as a solid powder with a purity of ≥98%. The unique diazabicyclooctane scaffold of Avibactam Sodium enables covalent, reversible inhibition of β‑lactamases without being hydrolyzed. Avibactam Sodium is also available as a reference standard for analytical method development, method validation, and quality control applications.

 

Product Parameters

---

Parameter	Specification
Product Name	Avibactam Sodium
CAS Number	1192491-61-4
Molecular Formula	C₇H₁₀N₃NaO₆S
Molecular Weight	287.23 g/mol
Appearance	White solid powder
Melting Point	＞208 ℃
Storage Condition	Sealed in dry,Room Temperature

 

Mechanism Of Action  

---

The β-lactamase enzyme initiates a nucleophilic attack on the amide bond of avibactam via serine, leading to ring opening and formation of a covalent complex that constitutes an inhibited enzyme state without hydrolysis; subsequent cyclization then restores the lactam ring to yield avibactam. The rate of nucleophilic attack-induced ring opening far exceeds that of cyclization, keeping the β-lactamase predominantly in an inhibited state. During this process, avibactam itself can be restored through a reverse reaction, conferring prolonged enzymatic inhibition. As a novel β-lactamase inhibitor with a non-lactam structural framework, avibactam irreversibly inhibits the lactamase enzyme of Mycobacterium tuberculosis.

 

Product Features

---

Avibactam (NXL-10, Chemicalbook 4) belongs to the diazaborubicene class of compounds and is currently regarded as the most promising novel β-lactamase inhibitor. Compared with the three marketed β-lactamase inhibitors, it exhibits prolonged efficacy, reversible covalent binding to the enzyme, and does not induce β-lactamase production.

 

Untoward E ffect

---

Avibactam alone does not cause serious adverse events; the most common side effects are local skin irritation at the application site (12%) and headache (6%). Other side effects include dry mouth, fever, nervousness, taste disturbances, headache, and hyperhidrosis, all of which are mild in severity. In summary, adverse events associated with avibactam are minor. When used in combination with antibiotics such as cefotaxime or cefuroxime, avibactam demonstrates good tolerability with no reported serious adverse reactions.

 

Contact Us

---

Searching for a dependable source of Avibactam Sodium for your antibacterial combination therapy manufacturing or analytical development program? Cosperpharm is your partner. Reach out to our team today for pricing, documentation, or technical support — we are here to support your pharmaceutical and research needs.